Role of histamine H4 receptor in allergic conjunctivitis in mice

Nakano, Yoshitaka; Takahashi, Yuji; Ono, Rie; Kurata, Yasunori; Kagawa, Yoto; Kamei, Chiaki

doi:10.1016/j.ejphar.2009.02.035

Cited by 33 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dual activation of H 1 receptor and H 4 receptor on sensory neurons, which in turn results in the excitation of histamine-sensitive afferents, may underlie the sensation of itch (Rossbach et al, 2011). These effects may translate into the nociceptive and antipruritic activities seen in animal models (Bell et al, 2004;Coruzzi et al, 2007;Dunford et al, 2007;Altenbach et al, 2008;Cowart et al, 2008;Nakano et al, 2009;Rossbach et al, 2009;Yamaura et al, 2009;Cowden et al, 2010b;Hsieh et al, 2010a,b). In both cases the effects of H 4 receptor antagonists appear to be mediated via modulation of neuronal activity.…”

Section: Functionmentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

et al. 2015

View full text Add to dashboard Cite

Section: Functionmentioning

confidence: 99%

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

et al. 2015

View full text Add to dashboard Cite

“…The number of eye scratching movements was counted according to Nakano's protocol. 24 In brief, eye scratching movement was defined by an uninterrupted cluster of rapid fore-or hind limb movements directed to the ocular surface.…”

Section: Evaluation Of Eye Scratching Movement After Lbns Applicationmentioning

confidence: 99%

Development of Latanoprost-Loaded Biodegradable Nanosheet as a New Drug Delivery System for Glaucoma

Kashiwagi

Ito

Haniuda

et al. 2013

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Citation: Kashiwagi K, Ito K, Haniuda H, Ohtsubo S, Takeoka S. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci. 2013;54:5629-5637. DOI:10.1167/iovs.12-9513 PURPOSE. We investigated the IOP reduction and safety of latanoprost-loaded biodegradable nanosheet (LBNS) as a new antiglaucoma drug delivery system (DDS).METHODS. We fabricated a 40 nm thick multilayered biodegradable nanosheet that is composed of chitosan and sodium alginate by means of the layer-by-layer method. Latanoprost isopropyl ester was loaded on the nanosheet to prepare 25, 2.5, and 0.25 lg/ cm 2 LBNSs. A nanosheet without latanoprost isopropyl ester (NS) and 0.005% latanoprost ophthalmic solution were prepared as controls. LBNSs or NS was applied to rat cornea, and IOP was monitored for 9 days. Local adverse effects and eye scratching movement also were investigated. The amount of latanoprost acid in aqueous humor and was measured in rabbits.RESULTS. The 0.25 lg/cm 2 LBNS and 0.005% latanoprost ophthalmic solution showed significant IOP reduction only for 1 day after application, whereas the IOP reduction rates of 2.5 lg/cm 2 LBNS at 1, 2, 4, 7, and 9 days after application were À27.0% 6 14.8%, À22.0% 6 16.7%, À25.8% 6 18.0%, À22.7% 6 20.9%, and À6.6% 6 17.0%, respectively. The 25 lg/cm 2 LBNS reduced IOP in a similar manner. The 25 lg/cm 2 LBNS induced transient hyperemia, whereas the 0.25 and 2.5 lg/cm 2 LBNSs did not exert any local adverse effects. The eye scratching movement test showed that application of 25 lg/cm 2 LBNS did not cause any irritation of the eye. Latanoprost acid was detected in aqueous humor up to 6 days after application of 2.5 lg/cm 2 LBNS.CONCLUSIONS. LBNS may be used as a novel antiglaucoma DDS.

show abstract

“…5,23,24 More recent identification of a fourth isoform of the histamine receptor, ie, the H 4 receptor, led to studies suggesting that this receptor may also play a role in the pathogenesis of ocular allergies. 25,26 Despite these observations, most of the drugs currently used to treat allergic conjunctivitis are either H 1 antagonists/inverse agonists or dual action H 1 antagonist/mast cell stabilizers. 6 Thus, it would seem that a drug with a broad spectrum (ie, one with potential for physiological effects at multiple receptor isoforms) of histamine receptor antagonism could have the potential to represent an advance over current therapeutic approaches.…”

Section: Discussionmentioning

confidence: 99%

“…18,19 Evidence for H 4 receptor involvement in conjunctivitis and rhinitis has been reported in mouse models of these allergic conditions. 25,32 In both of these reports, the H 4 receptor antagonist, JNJ7777120, significantly reduced allergic symptoms, and the effect could be ascribed to blockade of H 4 receptors. Combined treatment with JNJ7777120 and the H 1 antagonist levocabastine reduced signs and symptoms of allergic conjunctivitis to a greater extent than either agent alone.…”

Section: Notesmentioning

confidence: 99%

“…Combined treatment with JNJ7777120 and the H 1 antagonist levocabastine reduced signs and symptoms of allergic conjunctivitis to a greater extent than either agent alone. 25 This additive effect of the H 1 + H 4 receptors suggests that both receptors are involved in the etiology of the disease. In light of the potential role of the H 4 receptor in conjunctivitis, the H 4 receptor antagonist activity, and the effects on eosinophils observed in the preclinical model with alcaftadine, it is intriguing to speculate that antagonism of the H 4 receptor may contribute to its in vivo activity.…”

Section: Notesmentioning

confidence: 99%

See 1 more Smart Citation

Alcaftadine, a new antihistamine with combined antagonist activity at histamine H1, H2, and H4 receptors

Gallois-Bernos¹,

Thurmond²

2012

JRLCR

View full text Add to dashboard Cite

Current therapy for ocular allergy includes H 1 antihistamines, mast cell stabilizers, dual action antihistamines (H 1 antihistamines + mast cell stabilizers), and steroids. In this report, we describe the in vivo and in vitro characterization of alcaftadine, a recently approved antihistamine that exhibits a distinct set of therapeutic properties. When tested in a guinea pig model of conjunctivitis, alcaftadine prevented immediate allergic responses with an efficacy comparable with that of ketotifen, and was also able to attenuate delayed eosinophil influx with a potency similar to that of dexamethasone. Given recent reports suggesting a possible role for histamine H 2 or H 4 receptors in the etiology of ocular allergy, we examined the binding properties of alcaftadine at all histamine receptor types. Alcaftadine is a high affinity ligand for the H 1 receptor, with a pK i (8.5) that is comparable with that of other H 1 antihistamines. It also shows an higher affinity for the H 2 receptor than ketotifen. Alcaftadine exhibited modest binding affinity for the H 4 receptor (pK i = 5.8) with no affinity for the H 3 receptor. The affinity for the H 4 is higher than the value for ketotifen (pK i , 5). Using a cellular assay of H 4 receptor activity, alcaftadine was shown to act as a functional antagonist of H 4 receptor signaling. Overall, the studies suggest that alcaftadine is a histamine receptor antagonist with a broad spectrum of antihistamine activity and a unique combination of therapeutic effects. As such, it represents a new therapeutic option for the treatment of allergic conditions.

show abstract

Role of histamine H4 receptor in allergic conjunctivitis in mice

Cited by 33 publications

References 25 publications

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

Development of Latanoprost-Loaded Biodegradable Nanosheet as a New Drug Delivery System for Glaucoma

Alcaftadine, a new antihistamine with combined antagonist activity at histamine H1, H2, and H4 receptors

Contact Info

Product

Resources

About